AC Immune Ltd
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +27.9% | -8.5% | +42.0% | +2.8% | -5.5% | -8.6% | -9.9% | -9.8% | -10.0% | -11.0% | +9.4% | |
| – | +45.2% | -12.2% | +64.3% | +3.9% | -8.3% | -11.5% | -13.4% | -13.7% | -14.9% | -17.3% | +16.7% | |
| – | +145.9% | -27.4% | -9.6% | -37.1% | +11.9% | -45.0% | +28.9% | +7.8% | -3.3% | -28.5% | +44.8% | |
| – | +28.9% | +1.7% | +67.1% | -9.8% | +4.8% | -12.0% | -12.7% | -14.7% | -15.6% | -18.3% | +0.7% | |
| – | +4,722.4% | -98.2% | +50.6% | +6,213.4% | -95.7% | -15.8% | -44.9% | -21.2% | +159.1% | -77.9% | +5,832.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.1% | – | – | |
| – | +28.0% | +1.9% | +404.9% | 0.0% | +4.0% | -2.0% | -0.7% | -5.5% | +0.3% | -3.3% | +8.8% | |
| – | +15.9% | +4.0% | +611.8% | +0.5% | -0.1% | -1.6% | -0.3% | -0.7% | -3.5% | -2.7% | +8.7% | |
| – | +21.1% | +0.0% | +2.2% | +1.0% | +47.8% | +0.7% | +0.6% | +0.6% | -18.4% | -3.3% | +1.2% | |
| – | +13.5% | +69.0% | -49.4% | -1.3% | +87.7% | -10.0% | +14.1% | -42.6% | +32.2% | -36.3% | +14.7% | |
| – | +27.8% | -9.9% | -14.7% | +5.5% | -13.7% | -15.6% | -21.2% | -16.5% | -28.0% | -29.8% | +11.5% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +18.1% | +0.2% | +1.3% | +0.0% | -0.4% | +0.2% | -1.5% | +2.1% | -2.5% | +0.0% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.